HERON THERAPEUTICS INC (HRTX)

US4277461020 - Common Stock

2.34  +0.02 (+0.86%)

After market: 2.35 +0.01 (+0.43%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
86.3M
-2.60%		107.7M
24.80%		127.044M
17.96%		148.85M
17.16%
EBITDA
YoY % growth
-214.78M
4.69%		-171.81M
20.01%		-107.716M
37.31%		N/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
-217.8M
4.56%		-174.7M
19.79%		-110.615M
36.68%		-57.766M
47.78%
Operating Margin
-252.38%-162.21%-87.07%-38.81%
EPS
YoY % growth
-2.25
10.00%		-1.73
23.11%		-0.86
50.29%		-0.46
47.02%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.09
66.00%
Revenue
Q2Q % growth		33.456M
12.95%
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-13.515M
59.12%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.07
58.82%		-0.170.1058.07%
Q3 2023
Q2Q % growth		 -0.17
55.26%		-0.300.1343.02%
Q2 2023
Q2Q % growth		 -0.35
36.36%		-0.24-0.11-47.02%
Q1 2023
Q2Q % growth		 -0.27
57.14%		-0.21-0.06-30.40%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 34.233M
14.00%		31.595M2.638M8.35%
Q3 2023
Q2Q % growth		 31.43M
18.34%		33.303M-1.873M-5.62%
Q2 2023
Q2Q % growth		 31.76M
14.95%		32.33M-570K-1.76%
Q1 2023
Q2Q % growth		 29.62M
26.26%		30.281M-661K-2.18%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 5.26% -3.08% -20.72%
Revenue0% 2.85% 4.91% 3.43%